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Background
The availability of controller therapies at multiple
strengths is important to treat different severities of
asthma (NHLBI and GINA guidelines). The clinical
effect of medium-dose mometasone furoate/formoterol
(MF/F) combination administered via single inhaler had
never been characterized in asthmatic subjects versus
placebo. We investigated the effect of medium-dose
MF/F administered via an MDI on asthma deteriora-
tions (ie, severe asthma exacerbations) and pulmonary
function in moderately-severe asthmatics inadequately-
controlled on medium-dose inhaled corticosteroids
(ICS) ± long-acting b2-agonists (LABA).
Materials and methods
After 2-3-weeks open-label run-in with MF 200μgB I D ,
subjects (≥12 years) were randomized to 26-weeks treat-
ment BID with MF/F 200/10μg, MF 200μg, F 10μg, or
placebo. Coprimary endpoints were time-to-first asthma
deterioration over the treatment period (MF/F vs F),
and the area under the curve (AUC) of the change in
serial FEV1 [0-12 hr] to Week 12 (MF/F vs MF).
Results
781 subjects (mean: age=42.4 y, asthma duration=16.07
y, FEV1 % predicted=72.62%, reversibility=18.80%, ACQ
score=1.51) were randomized. MF/F increased the time-
to-first asthma deterioration and decreased the propor-
tion of subjects who experienced asthma deteriorations
(MF/F=30.4%; MF=33.9% [p=0.565]; F=54.0% [p<0.001];
placebo=55.6% [p<0.001]).M F / Ft r e a t m e n ti m p r o v e d
lung function more than MF within 5 minutes following
administration (p<0.001); mean Week-12 FEV1AUC0-12h
(L x h over baseline): MF/F=3.11, MF=1.30, F=1.93, and
placebo=0.57 (effect was maintained throughout the
treatment period). Adverse events were rare and similar
across treatment groups.
Conclusions
MF/F 200/10μg was more effective in reducing asthma
deteriorations and improving lung function in asth-
matics uncontrolled on medium-dose ICS±LABA than
placebo, MF or F.
Author details
1Asthma and Allergy Associates, P.C., Colorado Springs, CO, 80907, USA.
2Colorado Allergy and Asthma Centers, P.C., Denver, CO, 80230, USA.
3Merck
Research Laboratories, Kenilworth, NJ, 07033, USA.
4Sneeze, Wheeze, and Itch
Associates, Normal, IL, 61761, USA.
Published: 4 November 2010
doi:10.1186/1710-1492-6-S2-P16
Cite this article as: Nathan et al.: Efficacy and safety of combined
medium-dose mometasone furoate/formoterol (MF/F) in persistent
asthmatics. Allergy, Asthma & Clinical Immunology 2010 6(Suppl 2):P16.
* Correspondence: DrRNathan@aol.com
1Asthma and Allergy Associates, P.C., Colorado Springs, CO, 80907, USA
Full list of author information is available at the end of the article
Nathan et al. Allergy, Asthma & Clinical Immunology 2010, 6(Suppl 2):P16
http://www.aacijournal.com/content/6/S2/P16 ALLERGY, ASTHMA & CLINICAL 
IMMUNOLOGY
© 2010 Nathan et al; licensee BioMed Central Ltd.